-
Study aim
-
The efficacy of topical interferon alpha-2b in primary and recurrent pterygium
-
Design
-
The data collection tool was a two-part questionnaire. The first part contains patient’s identification and demographic information. The second part of questionnaire contains history and ophthalmic examination.
Ophthalmic examination(keratometery, size, grade, BCVA, UCVA, refraction) was done for all patients 4 times: before the first subconjunctival injection, the end of first month, third month, sixth month.
-
Settings and conduct
-
The study were performed on patients with Pterygium attending to Ophthalmology clinic of Baqiyatallah hospital, Tehran, Iran; whose disease has been confirmed by an ophthalmologist.
Patients were subconjunctivalally injected with interferon alpha-2b with 3million / ml every one month for two occasions. At the same time, a topical drop of interferon alpha-2b with a concentration of 1 million unit / ml for patients was initiated. The duration of use of this drop was three months, with the first month every 6 hours, the second month every 8 hours, and the third month every 12 hours.
-
Participants/Inclusion and exclusion criteria
-
The inclusion criteria were defined as: Any patients with primary pterygium; either unilaterally or bilaterally, who diagnosed by an ophthalmologist.
Exclusion criteria:
-Use of any local ophthalmic drug
-Patients with History of Refractive Surgery
-History of any eye diseases other than refractive disorders
-Pregnant or lactating women
-
Intervention groups
-
Subconjunctival injections of 3 million/ml Interferon alpha-2b was done for all patients two times: the first injection was done in the first day and second injection was performed at the end of first month. IFNα2b. Also IFNα2b 1 million/ml Topical eye-drops was given to all patients for three month.
-
Main outcome variables
-
The efficacy of topical interferon alpha-2b in primary and recurrent pterygium